Dexcom
Medical Affairs
Dr. Cherñavvsky received his medical degree from the University of Buenos Aires, Argentina. He completed his pediatric residency at the Children’s Hospital in Buenos Aires and his fellowship in pediatric nephrology at the Italian Hospital in Buenos Aires. He came to the University of Virginia in 1997 as a research fellow. He joined the faculty at UVA, and his seminal work was in the Center for Diabetes Technology where he was part of the development of the first closed-loop system tested in humans. He coordinated the 1st USA outpatient clinical trial of an artificial pancreas in 2011. He also conducted the 1st clinical trial using Artificial Pancreas in Latin America in 2016. As part of the UVA Center for Diabetes Technology, he conducted more than 30 clinical trials in five countries enabling emerging technology to be tested and later used for treatment of diabetes in children, adolescents, and adults. Dr. Chernavvsky is the author or co-author of numerous peer review articles, and is senior editor for the first edition of the Artificial Pancreas published in April 2019. In 2017, he joined TypeZero as a Chief Medical Officer and in 2019 he joined Dexcom as Senior Director of Medical Affairs.

Moderator of 1 Session

Session Type
INDUSTRY
Date
Thu, 23.02.2023
Room
Plenary Hall A6
Session Time
15:00 - 16:30
Session Description
Dexcom Continues to Lead in CGM Technology Across the Diabetes Spectrum - Industry Symposium Supported by Dexcom

Session Description: This is the first of 3 education programs sponsored by Dexcom, Inc. at ATTD 2023, titled “Dexcom Continues to Lead in CGM Technology Across the Diabetes Spectrum.” and moderated by Dr. Daniel Chernavvsky. This education program will focus on Dexcom CGM and its use with both our Type 1 and Type 2 diabetes patients. Real world experience and correlational outcomes of Dexcom G7 and its unique features will be shared by Dr. Emma Wilmot, as well as an introduction to the new 2GO-CGM study, focusing on the use of Dexcom CGM use in Type 2, intensive and non-intensive insulin treated patients by the primary investigator, Dr. Martin de Bock. Finally, the next generation Dexcom-Type Zero AID algorithm and first in-human study results will be presented by Drs. Stephen Patek, Enrique Campos-Nanez, Martin de Bock and Katharine Barnard-Kelly. Finally, the next generation Dexcom-Type Zero AID algorithm and first in-human study results will be presented by Drs. Stephen Patek, Enrique Campos-Nanez, Martin de Bock and Katharine Barnard-Kelly.

Presenter of 2 Presentations

Welcome & Introduction (ID 1121)

Lecture Time
15:00 - 15:05
Session Type
INDUSTRY
Date
Thu, 23.02.2023
Session Time
15:00 - 16:30
Room
Plenary Hall A6